Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Seres Therapeutics Inc has a consensus price target of $9.36 based on the ratings of 8 analysts. The high is $25 issued by HC Wainwright & Co. on March 8, 2023. The low is $1.25 issued by Chardan Capital on August 14, 2024. The 3 most-recent analyst ratings were released by Canaccord Genuity, Canaccord Genuity, and Chardan Capital on September 13, 2024, August 14, 2024, and August 14, 2024, respectively. With an average price target of $7.08 between Canaccord Genuity, Canaccord Genuity, and Chardan Capital, there's an implied 508.01% upside for Seres Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Seres Therapeutics (NASDAQ:MCRB) was reported by Canaccord Genuity on September 13, 2024. The analyst firm set a price target for $10.00 expecting MCRB to rise to within 12 months (a possible 758.37% upside). 11 analyst firms have reported ratings in the last year.
The latest analyst rating for Seres Therapeutics (NASDAQ:MCRB) was provided by Canaccord Genuity, and Seres Therapeutics maintained their buy rating.
There is no last upgrade for Seres Therapeutics
The last downgrade for Seres Therapeutics Inc happened on June 7, 2024 when Oppenheimer changed their price target from N/A to N/A for Seres Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Seres Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Seres Therapeutics was filed on September 13, 2024 so you should expect the next rating to be made available sometime around September 13, 2025.
While ratings are subjective and will change, the latest Seres Therapeutics (MCRB) rating was a maintained with a price target of $10.00 to $10.00. The current price Seres Therapeutics (MCRB) is trading at is $1.17, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.